Liminatus Pharma updates Nasdaq equity review
Liminatus Pharma, Inc. states that, following its previously announced merger with InnocsAI LLC, it believes its stockholders’ equity now exceeds $2.5 million as of the date of the report.
Rhea-AI Filing Summary
Liminatus Pharma, Inc. states that, following its previously announced merger with InnocsAI LLC, it believes its stockholders’ equity now exceeds $2.5 million as of the date of the report.
The company is awaiting a compliance determination from The Nasdaq Stock Market regarding the applicable stockholders’ equity requirement. Liminatus notes that, even if it is currently found compliant, Nasdaq will continue monitoring its equity levels and the company may face future delisting if a subsequent periodic report does not demonstrate compliance. The company characterizes these statements as forward-looking and refers to its SEC filings for additional risk factors.
Positive
- None.
Negative
- Ongoing Nasdaq delisting risk tied to equity levels: The company explains that Nasdaq will keep monitoring stockholders’ equity and it may be subject to future delisting if a later periodic report does not show compliance with the stockholders’ equity requirement.
Insights
Analyzing...
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Stockholders’ equity level: $2.5 million
1 metrics
Stockholders’ equity level
$2.5 million
Believed stockholders’ equity exceeds this amount as of July 29, 2026
Key Terms
stockholders’ equity requirement, Nasdaq listing rules, forward-looking statements, Emerging growth company
4 terms
stockholders’ equity requirement financial
"monitor the Company’s ongoing compliance with the stockholders’ equity requirement"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
Nasdaq listing rules regulatory
"regain compliance with the Nasdaq listing rules during any compliance period"
Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.
forward-looking statements regulatory
"Certain information contained in this report consists of forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Liminatus Pharma (LIMN) report about its stockholders’ equity?
Liminatus Pharma stated it believes its stockholders’ equity now exceeds $2.5 million as of the report date, following its merger with InnocsAI LLC. This figure is being considered as Nasdaq reviews the company’s compliance with its stockholders’ equity requirement.
What is Liminatus Pharma’s (LIMN) current status with Nasdaq listing compliance?
The company is awaiting a formal compliance determination from Nasdaq regarding the stockholders’ equity requirement. It also notes Nasdaq will continue to monitor equity levels and could initiate future delisting if a subsequent periodic report does not demonstrate ongoing compliance.
How does the InnocsAI LLC merger affect Liminatus Pharma (LIMN)?
Liminatus Pharma attributes its belief that stockholders’ equity now exceeds $2.5 million to the previously announced merger with InnocsAI LLC. This post-merger equity position is a key factor in Nasdaq’s evaluation of whether the company meets the continued listing stockholders’ equity standard.
What delisting risk did Liminatus Pharma (LIMN) disclose?
Liminatus Pharma disclosed that it may be subject to future Nasdaq delisting if, at the time of its next periodic report, it does not demonstrate compliance with Nasdaq’s stockholders’ equity requirement, even if Nasdaq initially determines that the company is currently in compliance.
How did Liminatus Pharma (LIMN) characterize its statements about Nasdaq compliance?
The company characterized its comments on Nasdaq compliance and stockholders’ equity as forward-looking statements. It cautioned that actual outcomes could differ materially and referred readers to its other SEC filings for additional factors that could affect future results and listing status.
AI-generated analysis. How Rhea-AI works. Not financial advice.
